



pulsar


Extension

PULSAR Extension: 156-week retinal fluid and PED outcomes in patients with nAMD receiving aflibercept 8mg

Michael W. Stewart,¹ Marion R. Munk,²⁻⁴ Praveen J. Patel,^{5,6} Paolo Lanzetta,^{7,8} Richard Gale,^{9,10} Javier Zarranz-Ventura,¹¹ Jean-François Korobelnik,^{12,13} Sobha Sivaprasad,^{5,6} Sergio Leal,¹⁴ Andrea Schulze,¹⁵ Tobias Machewitz,¹⁵ Peter Morgan-Warren,¹⁴ Xin Zhang,¹⁴ Aude Ambresin,¹⁶ Michael Singer,¹⁷ Timothy Y.Y. Lai,¹⁸ David T. Wong,¹⁹ Ehsan Rahimy,²⁰ Michael Javaheri²¹
on behalf of the PULSAR study investigators


¹Mayo Clinic College of Medicine and Department of Ophthalmology, Mayo Clinic, Jacksonville, FL, USA; ²Augenarzt-Praxisgemeinschaft Gutblick AG, Pfäffikon, Switzerland; ³Department of Ophthalmology, Inselspital, University Hospital Bern, Bern, Switzerland; ⁴Department of Ophthalmology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA; ⁵National Institute for Health Research Biomedical Research Centre, Moorfields Eye Hospital, NHS Foundation Trust, London, UK; ⁶UCL Institute of Ophthalmology, London, UK; ⁷Department of Medicine – Ophthalmology, University of Udine, Udine, Italy; ⁸Istituto Europeo di Microchirurgia Oculare (IEMO), Udine and Milan, Italy; ⁹Hull York Medical School, University of York, York, UK; ¹⁰York and Scarborough Teaching Hospital NHS Foundation Trust, York, UK; ¹¹Hospital Clínic de Barcelona, Universitat de Barcelona, Barcelona, Spain; ¹²CHU Bordeaux GH Pellegrin, Service d’Ophtalmologie, Place Amélie Raba Leon, 33000 Bordeaux, France; ¹³University of Bordeaux, INSERM, Bordeaux Population Health Research Center, UMR1219, F-33000, Bordeaux, France; ¹⁴Bayer Consumer Care AG Pharmaceuticals, Basel, Switzerland; ¹⁵Bayer AG, Berlin, Germany; ¹⁶Swiss Visio Montchoisi, Lausanne, Switzerland; ¹⁷University of Texas Health Science Center, San Antonio, TX, USA; ¹⁸Department of Ophthalmology & Visual Sciences, The Chinese University of Hong Kong, Hong Kong; ¹⁹Unity Health Toronto – St Michael’s Hospital, University of Toronto, Toronto, ON, Canada; ²⁰Byers Eye Institute, Stanford University School of Medicine, and Palo Alto Medical Foundation, Palo Alto, CA, USA; ²¹Roski Eye Institute, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA; Retina Specialists of Beverly Hills, Beverly Hills, CA, USA

PULSAR Extension Design



^aTo be eligible for PULSAR Extension, patients were required to have ≥ 1 BCVA and CRT assessments between Week 84 and Week 92. Masked transition period (W96–108) was followed by open-label part (W108–W156). ^bN-BL was an average of values from W84, W88, and W92. ^cOptional phase added while PULSAR was ongoing; therefore, not all patients were able to enroll due to time constraints. **2q8**, aflibercept 2 mg every 8 weeks; **8q12**, aflibercept 8 mg every 12 weeks; **8q16**, aflibercept 8 mg every 16 weeks; **BCVA**, best-corrected visual acuity; **BL**, baseline; **CRT**, central subfield retinal thickness; **nAMD**, neovascular age-related macular degeneration; **N-BL**, new baseline; **W**, week.

Mean BCVA and CRT Through Week 156^a



Mean number of injections from baseline to Week 96 (96 weeks)^c
 2 mg: 12.8
 8 mg: 9.0




Mean number of injections from Week 96 to Week 156 (60 weeks)^c
 8 mg: 4.9
 8 mg: 3.9

No new safety signals were identified through 156 weeks. The safety profile remained consistent with previous findings.

Note: At Week 156, the 2q8→8mg group (n=208) and 8mg group (n=417) reported LS mean (95% CI) changes from BL (MMRM) in BCVA of +4.6 (2.6, 6.6) letters and +3.4 (1.9, 4.9) letters, respectively, and in CRT of -145 (-155, -136) µm and -148 (-156, -140) µm, respectively. MMRM was used to generate BCVA/CRT LS means for the eFAS with BL BCVA/CRT as a covariate; treatment group (afibercept 8q12, 8q16, 2q8), visit, and stratification variables (geographic region [Japan vs rest of the world] and BL BCVA [<60 vs ≥ 60 letters]) as fixed factors; and terms for the interaction between visit and BL BCVA/CRT and the interaction between visit and treatment. ^aeFAS (observed cases). ^bPatients who were randomly assigned to the 8q12 or 8q16 groups at the beginning of the PULSAR study and continued treatment with aflibercept 8 mg through the PULSAR Extension. ^ceSAF (156-week completers; 2q8→8mg, n=186; 8q12, n=185; 8q16, n=190; 8mg, n=375). CI, confidence interval; eSAF, safety analysis set in the PULSAR Extension; ETDRS, Early Treatment Diabetic Retinopathy Study; LS, least squares; MMRM, mixed model for repeated measures.

Fluid Resolution: Patients with No Intraretinal and Subretinal Fluid at Week 156





- The proportion of patients with fluid resolution was maintained in the **aflibercept 2q8→8mg** group through 96 weeks and was **sustained after switching to 8 mg** through Week 156
- **Long-term fluid resolution** was observed in the 8mg group with extended dosing intervals through Week 156
- The proportion of patients with fluid resolution was **similar in the 2q8→8mg and 8mg groups** at Week 156

eFAS (LOCF). Fluid resolution defined as no IRF and no SRF in central subfield. Fluid status was evaluated pre-injection. eFAS (LOCF). ^aeSAF (156-week completers; 2q8→8mg, n=186; 8mg, n=375). IRF, intraretinal fluid; LOCF, last observation carried forward; SRF, subretinal fluid.

2q8→8mg Group: Patients with Fluid Resolution 4 and 8 Weeks After Active Injections




Aflibercept 2q8 dosing regimen through Week 96 of PULSAR																								
Day 1	W4	W8	W12	W16	W20	W24	W28	W32	W36	W40	W44	W48	W52	W56	W60	W64	W68	W72	W76	W80	W84	W88	W92	W96
X	X	X		X	o	X	o	X	o	X	o	X	o	X	o	X	o	X	o	X	o	X	o	X




Stippled boxes = initial treatment phase; X = active injection; o = sham injection. eFAS (LOCF). Patients entering the PULSAR extension: 2q8→8mg group (n=208). Presence of fluid was evaluated prior to active injection administration. Aflibercept 2 mg injections were given at Weeks 0, 4 and 8, and then 8-weekly from Week 16 to Week 88. The first aflibercept 8 mg injection was administered at Week 96.

2q8→8mg Group: Proportion of Patients with Fluid Resolution 4 and 8 Weeks After Aflibercept 2 mg and 8 mg Injections

Difference in Proportion of Patients with Fluid Resolution 4 and 8 Weeks After the Last 2 mg Injection




Difference in Proportion of Patients with Fluid Resolution 4 and 8 weeks After the First 8 mg Injection



Sub-RPE Fluid: PED Outcomes

- Pigment epithelial detachment (PED) is characterized by the separation of the RPE from the Bruch's membrane, resulting in a space that can be filled with fluid, blood, drusen, or fibrovascular material
- The neovascular lesion complex (LC) is comprised of the serous (sub-RPE fluid) and fibrovascular component



Objective:

To assess sub-RPE fluid over 156 weeks in patients who switched from aflibercept 2 mg to 8 mg, and who stayed on aflibercept 8 mg


Outcome measures^a:

- Proportion of patients with sub-RPE fluid
- Mean thickness of sub-RPE fluid in patients with serous component of PED involving the foveal center

PED characteristics at PULSAR baseline ^b	2q8→8mg (n=208)	All 8mg (n=417)
Patients with sub-RPE fluid, n (%)	110 (52.9)	210 (50.4)
Patients with sub-RPE fluid with involvement of foveal center, n (%)	24 (11.5)	52 (12.5)

^aAssessed using SD-OCT at Wisconsin Reading Center. ^beFAS. eFAS, extension full analysis set; RPE, retinal pigment epithelium; SD-OCT, spectral-domain optical coherence tomography

Patients with Presence of Sub-RPE Fluid Through Week 156^a




Mean number of active injections over 48-week periods:^b

- At **Week 96**, a **lower proportion** of patients had presence of sub-RPE fluid **with aflibercept 8 mg** than with aflibercept 2 mg
- At **Week 156**, the **proportion of patients** with presence of sub-RPE fluid was **generally maintained in the 8mg group**
- Results in the **2q8→8mg** group were **comparable to those of the 8mg group**, with **fewer aflibercept 8 mg injections** (following the switch) compared with previous aflibercept 2 mg injections over the same time periods

^aeFAS, observed cases (2q8→8mg, n=208; 8mg, n=417); ^beSAF (156-week completers; 2q8→8mg, n=186; 8mg, n=375).


Reduction of Proportion of Patients with Presence of Sub-RPE Fluid at Key Timepoints

Patients with presence of sub-RPE fluid




- At Week 96, the proportion of patients with presence of **sub-RPE fluid** decreased from **52.9% to 19.3%** and from **50.4% to 14.4%** at **W96** in patients receiving **afibercept 2 mg and 8 mg**, respectively
- From **W96 to W156**, the proportion of patients with presence of sub-RPE fluid in the **2q8→8mg** group decreased further following **switch to afibercept 8 mg**, while the proportion of patients in the 8mg group remained stable

Thickness of Sub-RPE Fluid Involving the Foveal Center through Week 156



- **Marked reductions in thickness of sub-RPE fluid** involving the foveal center were achieved with **aflibercept 2 mg and 8 mg at Week 12 and sustained through Week 96**
- **Further reductions** were observed at **Week 156** in patients who **switched from aflibercept 2 mg to 8 mg** and in patients who continued to receive **aflibercept 8 mg**

Reductions in Thickness of Sub-RPE Fluid Involving the Foveal Center at Key Timepoints





- From **BL to Week 96**, the thickness in sub-RPE fluid involving the foveal center decreased by **78.4%** and **88.5%** in patients who received aflibercept 2 mg and 8 mg, respectively
- **At Week 156**, these values decreased further to **96.5%** in patients who switched from aflibercept 2 mg to 8 mg, and to **94.0%** in those who received aflibercept 8 mg throughout

^aPatients with sub-RPE fluid presence at center point, observed cases. ^bCalculated as the mean change from BL in thickness of sub-RPE fluid presence at center point at a particular timepoint divided by the BL value, then multiplied by 100.

Conclusions

- Early **improvements in fluid and PED outcomes** were **generally maintained through Week 96** and **sustained or improved from Week 96 to Week 156** in the following patient groups:
 - **2q8→8mg** group following switch from aflibercept 2 mg to aflibercept 8 mg, with **fewer injections**
 - **8mg** group who had been receiving aflibercept 8 mg over **extended dosing intervals**
- At Week 156, the proportion of patients with IRF, SRF, and sub-RPE **fluid resolution** was **comparable in both groups**
 - In the **2q8→8mg** group, IRF and SRF **re-accumulation** between 4 and 8 weeks was **lower after the first 8 mg injection** in the PULSAR extension compared with after the last 2 mg injection in PULSAR



^aeFAS (LOCF).